Regulation of oxidative stress and redox systems has important roles in carcinogenesis and cancer progression, and for this reason has attracted much attention as a new area of cancer therapeutic targets. Glutathione peroxidase 4 (GPX4), an antioxidant enzyme, has biological important functions such as signaling cell death by suppressing peroxidation of membrane phospholipids. However, few studies exist on the expression and clinical relevance of GPX4 in malignant lymphomas such as diffuse large B-cell lymphoma. In this study, we assessed the expression of GPX4 immunohistochemically. GPX4 was expressed in 35.5% (33/93) cases of diffuse large B-cell lymphoma. The GPX4-positive group had poor overall survival (P = 0.0032) and progression-free survival (P = 0.0004) compared with those of the GPX4-negative group. In a combined analysis of GPX4 and 8-hydroxydeoxyguanosine (8-OHdG), an oxidative stress marker, there was a negative correlation between GPX4 and 8-hydroxydeoxyguanosine (P = 0.0009). The GPX4-positive and 8-hydroxydeoxyguanosine-negative groups had a significantly worse prognosis than the other groups in both overall survival (P = 0.0170) and progression-free survival (P = 0.0005). These results suggest that the overexpression of GPX4 is an independent prognostic predictor in diffuse large B-cell lymphoma. Furthermore, in vitro analysis demonstrated that GPX4-overexpressing cells were resistant to reactive oxygen species-induced cell death (P = 0.0360). Conversely, GPX4-knockdown cells were sensitive to reactive oxygen species-induced cell death (P = 0.0111). From these data, we conclude that GPX4 regulates reactive oxygen species-induced cell death. Our results suggest a novel therapeutic strategy using the mechanism of ferroptosis, as well as a novel prognostic predictor of diffuse large B-cell lymphoma.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype that accounts for one third of all newly diagnosed malignant lymphoma cases and over 80% of aggressive lymphomas [1] . DLBCL shows an aggressive behavior with a median survival of <1 year in untreated patients [1] . DLBCL includes a large number of disparate types distinguished by morphology, phenotype, gene expression profiles, and clinical outcomes [1] . Although there is an ongoing effort to classify DLBCL in order to treat by specific subtype [2] , individual clinical course varies greatly. Therefore, it is becoming increasingly important to find new prognostic markers [3] [4] [5] .
Tumor cells experience more oxidative stress than normal cells because of their high growth rate and higher oxygen requirement. To reduce oxidative stress, tumor cells develop various effective antioxidant systems, such as increased expression of the thioredoxin-thioredoxin reductase system [6] and the cystine/glutamic acid transporter (xc − ) system [7, 8] . These antioxidant systems and related molecules are essential for cancer progression and are hence targeted by anticancer drugs and used as biomarkers in a variety of cancers [9] [10] [11] . Glutathione peroxidase (GPX) is an intracellular antioxidant enzyme responsible for reducing peroxidized phospholipids. The GPX family member GPX4, also known as phospholipid-hydroperoxide glutathione peroxidase, is considered one of the most important antioxidant enzymes in mammals [12] [13] [14] . Recently, there have been reports suggesting that overexpression or depletion of GPX4 is responsible for tumorigenesis and tumor progression [15] [16] [17] [18] [19] [20] [21] . However, the frequency of GPX4 expression in malignant lymphoma including DLBCL, its histological relevance, and its relevance prognosis are not currently known.
In the present study, we clarify that GPX4 overexpression contributes to poor prognosis in DLBCL via inhibition of reactive oxygen species (ROS)-induced cell death by clinicopathologic study and in vitro cell death analysis.
Materials and methods

Patients and pathological specimens
We examined pathological specimens obtained from 93 patients with DLBCL at Tokyo Medical and Dental University Hospital, Tokyo, between 2000 and 2014. Of the 93 patients, 47 received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy, and 46 received CHOP therapy as induction therapy. Pathologic diagnosis was confirmed according to the WHO criteria by two pathologists (KY and MK). Specimens were obtained by biopsy or surgical resection, fixed in 10 % neutralized formalin, and embedded in paraffin according to routine protocols for conventional histopathological examination. Informed consent was obtained from all patients, and the study was approved by the ethics committees of Tokyo Medical and Dental University. All procedures were performed in accordance with the ethical standards established by these committees (M2000-1818).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue was sliced at a thickness of 4 μm, and the sections were placed on silanecoated slides and deparaffinized. Heat-based antigen retrieval, endogenous peroxidase blockade using 3% hydrogen peroxide, and blocking were performed with normal sera. The primary antibodies used were GPX4, 8-OHdG (15A3), CD20, CD10, bcl-6, and MUM-1 ( Table 1) . The specimens with primary antibodies were incubated overnight at 4°C. Primary antibodies were detected using an ABC Kit (Vector Laboratories, Burlingame, CA, USA) for 8-OHdG, CD20, CD10, and MUM-1 and Novolink Polymer Detection Systems (Leica, Wetzlar, Germany) for GPX4 and bcl-6. The color development was performed using diaminobenzidine (DAB; Nichirei Bioscience, Japan) or the HISTOFINE simple stain AP series (Nichirei Bioscience). Immunohistochemical expression of CD20 was used for diagnosis of DLBCL, and CD10, bcl-6, and MUM-1 were used to classify DLBCL into germinal center B (GCB) and non-GCB groups according to Hans algorithm [22] . For double immunostaining, heat treatment and blocking were performed between each step, and detection was performed using HISTOFINE simple stain AP series with Vector Blue (Vector Laboratories) or Novolink Polymer Detection Systems with DAB.
Preparation of RNA and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for DLBCL tissue sample RNA was extracted from fresh-frozen DLBCL samples using an RNeasy Mini Kit (Qiagen, Hilden, Germany), and reverse transcriptase reaction was performed using TaqMan 
Cell lines and culture
The LCL-K cell line obtained from human peripheral blood B cells with Epstein-Barr virus infection was established at the Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan [23] . The cells were cultured in RPMI-1640 medium with L-glutamine and phenol red (Wako Pure Chemical Industries, Ltd., Osaka, Japan) containing 10% fetal bovine serum and 1% penicillin-streptomycin solution. Cells were passaged at a ratio of 1:5-1:8 every 2-3 days.
Establishment of GPX4-overexpressing LCL-K cell line using recombinant lentiviruses and lentiviral transduction Human GPX4, 3× FLAG, and 3′-UTR of GPX4 were subcloned using Raji cell cDNA and 3× FLAG control vector. They were subsequently inserted into mammalian expression vectors containing the cytomegalovirus promoter (Sigma-Aldrich, St. Louis, MO, USA). The GPX4 gene with attB sites was amplified by PCR using the Expand High Fidelity PCR System (Roche Diagnostics, Somerville, NJ, USA). Establishment of GPX4-knockdown LCL-K cell line by lentiviral shRNA silencing of GPX4
GPX4 shRNA lentiviral vector was constructed by annealing two oligonucleotides (forward primer, 5′-GA TCTCGGCACATGGTTAACCTGGAGCTTCCTGTCAC TCCAGGTTAACCATGTGCCTTTTTTA-3′, and reverse primer, 5′-AGCTTAAAAAAGGCACAGGTTAACCTG GAGTGACAGGAAGCTCCAGGTTAACCATGTGCCG A-3′) pretreated at 95°C for 5 min and gradually cooled down to room temperature. The annealed products were cloned into pSUPER driven by a human H1 promoter, and the GPX4-silenced LCL-K cell line was generated after puromycin selection. GPX4 knockdown was confirmed at the mRNA level by qRT-PCR and at the protein level by western blot.
ROS detection by flow cytometry in LG and LC cells
To detect intracellular ROS in LCL-K cells, CellROX Deep Red Reagent (Thermo Fisher Scientific) was used. This reagent freely enters the cells and becomes highly fluorescent after being oxidized by ROS [24, 25] . GPX4-overexpressing LCL-K cells and control vector-transfected LCL-K cells were seeded at a density of 2 × 10 5 cells/well in a 24-well culture plate with 500 μl media/well and treated with 20 μM tertbutyl hydroperoxide (TBHP), a major inducer of oxidative stress [26, 27] , for 6 h. As a negative control, 500 mM Nacetylcysteine (NAC) was pretreated and incubated for 1 h. After TBHP and NAC treatment, the medium was discarded, and cells were washed with phosphate-buffered saline (PBS). Subsequently, the cells were incubated with 1 μM CellROX Deep Red Reagent for 30 min at 37°C, and the cultures were analyzed by flow cytometry.
Assessment of cell viability upon treatment of LCL-K cells with TBHP and etoposide
LCL-K cell viability upon treatment with TBHP and etoposide was analyzed using the following methods. The cells were seeded at a density of 2 × 10 5 cells/well in a 24-well culture plates with 500 µL media/well and treated with 20 μM TBHP for 6 h and 250 nM etoposide for 24 h. After treatment with TBHP or etoposide, the medium was discarded and the cells were washed with PBS. Propidium iodide was added to each well and incubated at 37°C in the dark for 10 minutes. The samples were then analyzed by flow cytometry by a BD FACSCanto II analyzer (Becton Dickinson and Company, Franklin Lakes, NJ, USA).
Statistical analysis
Correlations between the two groups were determined with the χ 2 -test and Fisher's exact test. Overall survival (OS) duration was calculated from the date of diagnosis to the date of last follow-up or death. Progression-free survival (PFS) duration was calculated from the date of diagnosis to the time of progression or death. Kaplan-Meier survival curves were used to estimate OS and PFS rates, and the logrank test was used to assess differences in survival between groups. Univariate and multivariate analyses were performed with the Cox proportional hazard regression model. Mann-Whitney's U-test was used to evaluate the difference in the analysis of mRNA expression by qRT-PCR. The Student's t-test was used to determine the statistical significance of western blot band intensity or qRT-PCR expression. All differences with a P ≤ 0.05 were considered statistically significant. Ekuseru-Toukei version 1.15 (Social Survey Research Information Co., Ltd, Tokyo, Japan, 2012) was used for all the analyses.
Results
GPX4 and 8-OHdG immunohistochemistry in patients with DLBCL and assessment of positive cells
To evaluate GPX4 expression in DLBCL, we performed immunostaining (Fig. 1a, b) . The DLBCL cases were classified as GPX4-positive or GPX4-negative. To qualify as GPX4-positive, at least 50% of the DLBCL cells were required to test positive for GPX4 in the immunohistochemistry assay. Of the 93 patients, 33 cases (35.5%) were GPX4-positive. GPX4 protein was detected in the cytoplasm of the DLBCL cells.
8-OHdG is known as an end product of oxidative damage to DNA and known to be a sensitive oxidative stress biomarker. 8-OHdG expression was considered positive when >50% of the DLBCL cells in a specimen were stained. In our study, 27 out of 68 evaluated cases (39.7%) were positive for 8-OHdG, which was expressed in the nucleus of the DLBCL cells (Fig. 1c, d ). Double immunostaining of GPX4 and 8-OHdG revealed that their expression was mutually exclusive (Fig. 1e) .
Expression analysis of GPX4 mRNA in DLBCL
To determine whether GPX4 is overexpressed at the protein level or at the mRNA level in DLBCL, we first evaluated the GPX4 protein expression level in 48 DLBCL cases by immunohistochemistry and, depending on the results, divided into two groups, GPX4-positive and GPX4-negative group, according to the criteria described above. We then performed qRT-PCR to measure mRNA expression level using frozen samples of DLBCL. As shown in Supplementary Data 1, there was no significant differences in GPX4 mRNA between GPX4-positive and GPX4-negative groups (P = 0.4433).
Clinical significance of GPX4 overexpression in DLBCL
To evaluate the relationship between clinical outcome and GPX4 expression in DLBCL, various clinical features were investigated. GPX4 positivity was significantly correlated with age (P = 0.0292), and bone marrow involvement (P = 0.0406) ( Table 2 ). The staining patterns did not differ by patient gender, Ann Arbor staging classification, lactate dehydrogenase, performance status, IPI score, B symptoms, extranodal site, or Hans algorithm.
GPX4-positive group showed poor prognosis in OS/ PFS
We next investigated the correlation between GPX4 positivity and patient prognosis. Kaplan-Meier analysis revealed that the GPX4-positive group had significantly worse OS (Fig. 2a , P = 0.0032) and PFS ( Fig. 2b , P = 0.0004) than the GPX4-negative group.
We then tested 10 parameters, including age, gender, Ann Arbor stage, lactate dehydrogenase, performance status, B symptom, extranodal site, bone marrow involvement, Hans algorithm, and GPX4 expression by multivariate analysis using the Cox proportional hazard model (Table 3) . We found that the performance status 2-4 (vs. performance status 0-1, hazard ratio 4.5595, P = 0.0034) and GPX4-positivity (vs. GPX4-negativity, hazard ratio 4.5345, P = 0.0009) independently predicted shorter OS.
Inverse correlation between GPX4 and 8-OHdG expression
In order to test the hypothesis that GPX4-expressing DLBCL cells show less-intracellular ROS accumulation, we analyzed the correlation between GPX4 and 8-OHdG expression immunohistochemically. There was a significant inverse correlation between GPX4 and 8-OHdG positivity (χ 2 = 11.013, df = 1, P = 0.0009) ( Table 4) . Next, to analyze whether this combination of GPX4 and 8-OHdG expression predicts patient prognosis, we built survival curves (Kaplan-Meier analysis, Fig. 3 ). Patients with DLBCL were divided into four subgroups as follows: GPX4-negative and 8-OHdG-negative group, GPX4-negative and 8-OHdG-positive group, GPX4-positive and 8-OHdG-negative group, and GPX4-positive and 8-OHdG- a Kaplan-Meier analysis shows that the GPX4-positive group had a significantly worse OS (P = 0.0032) than GPX4-negative group.
b Kaplan-Meier analysis shows that the GPX4-positive group had a significantly worse PFS (P = 0.0004) than GPX4-negative group positive group. The GPX4-positive and 8-OHdG-negative group showed the worst prognosis, though there were no significant differences between the four subgroups in both OS and PFS ( Fig. 3a and b ). Subsequently, we divided patients into two groups: the GPX4-positive and 8-OHdG-negative group and all remaining patients. The GPX4-positive and 8-OHdG-negative group showed significantly poorer prognosis than the other groups, in both OS (P = 0.0170, Fig. 3c ) and PFS (P = 0.0005, Fig. 3d ).
Expression of GPX4 regulates ROS-induced cell death in LCL-K cell
Based on the finding that GPX4 overexpression in DLBCL correlated with poor patient prognosis and negatively correlated with intracellular ROS accumulation as determined by 8-OHdG staining, we hypothesized that overexpression induces resistance of tumor cells to ROS-induced cell death. Accordingly, reducing GPX4 expression should sensitize cells to ROS-induced death. To test this hypothesis, we used in vitro systems. We established LG and LC cells by transfection with a lentiviral vector (Fig. 4a) . Overexpression of GPX4 in LG cells was detected at the mRNA level by qRT-PCR (Fig. 4b) and at the protein level by western blot (Fig. 4c and d) . We then measured the difference in accumulation of ROS between LG and LC cells under treatment with TBHP by flow cytometry using Cell-ROX Deep Red Reagent. The fluorescent signal was less intense in LG-1 than in LC-1, indicating that LG-1 had lessintracellular ROS accumulation than LC-1. Thus, GPX4 overexpression inhibited the accumulation of intracellular ROS (Fig. 4e) . We then measured viability of cells treated with etoposide or TBHP to LG monoclones (LG-1, LG-2,
LG-3, and LG-4) and LC monoclones (LC-1, LC-2, LC-3, The frequency of GPX4-positive cases was significantly correlated with that of 8-OHdG-positive cases by Pearson Chi-square test (χ² = 11.01308, df = 1, P = 0.0009) Fig. 3 Inverse correlation between GPX4 and 8-OHdG expression. a GPX4-positive and 8-OHdG-negative groups show the worst prognosis, though there were no significant differences in OS between the four subgroups. b GPX4-positive and 8-OHdG-negative groups show the worst prognosis, though there were no significant differences in PFS between the four subgroups. c GPX4-positive and 8-OHdGnegative groups show significantly poorer prognosis in OS than the other groups (P = 0. 0170). d GPX4-positive and 8-OHdG-negative groups show a significantly poorer prognosis in PFS than the other groups (P = 0.0005) and LC-4) ( Fig. 4f and g ). The mean cell death rate was significantly suppressed in LG compared with LC cells after treatment with TBHP (P = 0.0170, Fig. 4h ), but it was not significantly different after treatment with etoposide (P = 0.1481, Fig. 4i ).
We established a GPX4-knockdown cell line by lentiviral shRNA silencing of GPX4. Knockdown efficiency of GPX4 at the mRNA level was quantified by qRT-PCR ( Fig. 5a ; P = 0.0306) and at the protein level by western blot (Fig. 5b and c) . We measured cell viability upon treatment with etoposide and TBHP and found that cell death rate was significantly increased in GPX4-knockdown LCL-K cells compared with that of control LCL-K cells after treatment with TBHP (P = 0.0111, Fig. 5d ). However, no significant difference was detected after treatment with etoposide (P = 0.1574, Fig. 5e ).
Discussion
GPX4, a selenoprotein and an intracellular antioxidant, is the only antioxidative enzyme that can directly reduce phospholipid hydroperoxides generated in biological membranes. It has an important role in oxidative homeostasis. It is known to show several different modes of intracellular localization: to the cytoplasm (cGPX4), mitochondria (mGPX4), and nucleolus (nGPX4) [28] . In normal somatic cells, expression level of the cGPX4 protein is ten times higher than that of mGPX4, and the expression level of nGPX4 is very low [29] .
Deficiency in GPX4 is reported to be associated with fetal death, male infertility, and hepatic and cardiac cell death in mice [14, 30] . Almost all normal mammalian cells show GPX4 activity, particularly abundant in testis, adipose tissue and retina [30, 31] . However, GPX4 is hardly detectable in lymphocytes by immunohistochemistry [32] and has decreased expression at the mRNA level [21] , though its enzymatic activity is detected to some extent [33] .
Although there are few reports of GPX4 in tumor tissue, GPX4 was found to be increased in colon carcinomas [15] and in hepatocellular carcinomas [16] , and decreased GPX4 level has been reported in pancreatic cancer [17] , breast cancer cells [18] , clear cell renal cell carcinomas [19] , and gastric cancer [21] . A variant of the gene encoding GPX4 has been reported to influence prostate cancer risk [20] . Despite these reports, there is yet no consensus on the expression and role of GPX4 in tumors. To the best of our knowledge, no study has yet assessed the relationships between GPX4 expression and patient prognosis in malignant lymphoma. However, we show here that there was no significant difference in mRNA level between the GPX4-positive group and GPX4-negative group, which suggests that post-transcriptional regulation, such as the ubiquitinproteasome system, may be involved in the expression of GPX4 protein in malignant lymphoma, including DLBCL.
In this study, 33/93 DLBCL cases were positive for GPX4, which was overexpressed compared with nonneoplastic B cells. The GPX4-positive group showed significantly poorer prognosis in OS and PFS. Moreover, GPX4 overexpression was an independent prognostic predictor. These results suggest that GPX4 overexpression might result in poor prognosis by a different mechanism than the existing prognostic predictors of DLBCL. It is possible that we only detected cytoplasmic GPX4 because of its abundant endogenous distribution compared with that of mitochondrial or nucleolus GPX4. However, cytoplasmic positivity of GPX4 might suggest the importance of cytoplasmic GPX4 in particular in tumor cell survival; Imai et al. [30] reported that only cytoplasmic GPX4 knockout results in embryonic lethality in mice . Considering that LCL-K cells demonstrated resistance to cell death after treatment with TBHP, which is ROS generator, but not after treatment with etoposide, which is known as nucleolus stressor [34] , GPX4-overexpressing tumor cells are likely to acquire the ability to neutralize ROS and thus combat oxidative stress. Overexpression of redox-regulating enzymes such as thioredoxin and glutamate-cysteine ligase in patients with DLBCL has been reported to lead to poor prognosis owing to the ability of tumor cells to cope with oxidative stress from ROS-generating anticancer drugs such as doxorubicin, vincristine, and cyclophosphamide [35] .
However, the exact roles of oxidative stress and the antioxidants that detoxify in cancer progression have been controversial, because oxidative stress can promote or suppress tumor development in different contexts [36] . Partly owing to the complexity of the relationships between oxidative stress and the redox system, there is no consensus on the relationship between aberrant expression of GPX4 and patient prognosis in human tumors. Nevertheless, there are relatively more reports showing that high expression of redox enzymes in tumor cells leads to poor prognosis [37, 38] .
Recently, Yang et al. [39] proposed a non-apoptotic form of cell death called ferroptosis that can be triggered by inactivation of GPX4 or depletion of intracellular i Mean cell death rate was not significantly different between LG and LC cells after treatment with etoposide (P = 0.1481); n.s., nonsignificant glutathione. DLBCL is one of the cancer cell types that are highly sensitive to ferroptosis, for unknown reasons [39, 40] . If these observations also apply to our results, the poor prognosis of patients with GPX4 overexpression may be owing to suppression of ferroptosis. To determine whether our result is related to ferroptosis, we would need to verify whether cell death rate increases under treatment with GPX4 inhibitors such as ferrostatin-1 and vitamin E [40] or GPX4-inhibitory peptide [41] . Though many aspects of ferroptosis remain unexplained, such as the execution factor and the substances detected downstream [40] , these reports suggest that GPX4 is unique and different from other antioxidants. GPX4 has the potential to become a new therapeutic target as research on GPX4 advances, with the elucidation of the structure of GPX4, for example ref. [41] .
In conclusion, we demonstrate that GPX4 overexpression is associated with poor prognosis in patients with DLBCL and GPX4 overexpression decreases ROSinduced cell death in vitro in LCL-K cells. Although several questions, such as the mechanism of the overexpression of GPX4, remain unsolved, and prospective studies must be performed with regard to potential clinical applications, GPX4 has the potential to become a novel anticancer drug target, as well as a prognostic predictor. Fig. 5 GPX4 knockdown promotes ROS-induced cell death in LCL-K cells. a Knockdown efficiency of GPX4 was detected at the mRNA level by qRT-PCR. GPX4 mRNA expression level was significantly decreased in GPX4-knockdown LCL-K cells (P = 0.0306). b Knockdown efficiency of GPX4 was detected at the protein level by western blot. c Densitometry analysis shows that GPX4 band intensity was significantly decreased in GPX4-knockdown LCL-K cells (P = 0.0013). d Cell death rate was significantly increased in GPX4-knockdown LCL-K cells compared with that of control LCL-K cells after treatment with TBHP (P = 0.0111). e Mean cell death rate was not significantly different between LG and LC cells after treatment with etoposide (P = 0.1574). shGPX4; GPX4-knockdown LCL-K cells.;*P < 0.05; n.s., non-significant
